Pre-made Cibisatamab benchmark antibody (Bispecific mAb with Domain Crossover, anti-CEACAM5/CD66e;CD3E therapeutic antibody, Anti-CEA;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Anti-CEACAM5/CD66e;CD3E therapeutic antibody (Pre-made Cibisatamab biosimilar,Bispecific mAb with Domain Crossover, Anti-CEA;T3E/TCRE/IMD18 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cibisatamab, an investigational drug, is a bispecific antibody, which means it binds to two different proteins: one called CEACAM5 on the surface of some colorectal cancer cells and another on T cells called CD3.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-104-1mg	1mg	Inquiry
GMP-Bios-ab-104-10mg	10mg	Inquiry
GMP-Bios-ab-104-100mg	100mg	Inquiry
GMP-Bios-ab-104-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Cibisatamab biosimilar, Bispecific mAb with Domain Crossover: Anti-CEACAM5;CD3E therapeutic antibody
INN Name	Cibisatamab
Target	CD66e;CD3E
Format	Bispecific mAb with Domain Crossover
Derivation	Bispecific antibody
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa;Lambda
Highest_Clin_Trial (Jan '20)	Phase-I/II
Est. Status	Active
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	None;None
Year Proposed	2017
Year Recommended	2018
Companies	Roche
Conditions Approved	na
Conditions Active	Non-small cell lung cancer;Colorectal cancer
Conditions Discontinued	Solid tumours
Development Tech	na